FDA Approves Outlook Therapeutics' LYTENAVA as First Branded Bevacizumab for Wet AMD After Fourth Attempt

On July 24, 2026, the FDA approved Outlook Therapeutics' LYTENAVA (bevacizumab-vikg) as the first ophthalmic formulation of bevacizumab for wet AMD, ending a regulatory saga involving three prior rejections and a successful Formal Dispute Resolution appeal. This milestone triggered executive rewards; on July 21, 2026, Outlook Therapeutics approved stock options and cash bonuses of $420,000 for CEO Robert C. Jahr and $200,000 for CFO Lawrence A. Kenyon, contingent on FDA approval by July 31, 2026.

Executive compensation structure

• ▪The Compensation Committee of Outlook Therapeutics approved the executive incentives in recognition of 2025 and 2026 regulatory efforts and the non-payment of 2025 annual bonuses.
• ▪Outlook Therapeutics approved new equity and cash incentives for its Chief Executive Officer and Chief Financial Officer on July 21, 2026.

FDA approval contingent bonuses

• ▪The cash bonuses for Outlook Therapeutics' executives are contingent on the FDA approving ONS-5010 and rendering a favorable decision on the Biologics License Application by July 31, 2026.
• ▪Outlook Therapeutics' Chief Executive Officer Robert C. Jahr and Chief Financial Officer Lawrence A. Kenyon received cash bonus opportunities of $420,000 and $200,000, respectively.

Stock option grants

• ▪The stock options for Outlook Therapeutics' executives were granted under the 2024 Equity Incentive Plan at an exercise price of $1.4304 per share.
• ▪Outlook Therapeutics granted stock options to purchase 100,000 shares to Chief Executive Officer Robert C. Jahr and 210,078 shares to Chief Financial Officer Lawrence A. Kenyon.

ONS-5010 regulatory review

• ▪The U.S. Food and Drug Administration approved Outlook Therapeutics' LYTENAVA (bevacizumab-vikg) for treating wet age-related macular degeneration on July 24, 2026.
• ▪The approval of LYTENAVA marks the first FDA-approved ophthalmic formulation of bevacizumab for wet age-related macular degeneration in the United States.
• ▪The FDA approval of LYTENAVA followed three prior rejections in August 2023, August 2025, and December 2025, and was cleared after a Formal Dispute Resolution appeal.

Option vesting terms

• ▪The stock options granted to Outlook Therapeutics' executives vest and become exercisable on July 21, 2027.
• ▪Vesting of the stock options is contingent upon the executives' continued service with Outlook Therapeutics through the July 21, 2027 vesting date.